Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 8/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745801 | 0.84 | ALDH1A1 (0.42) | ALDH1A1DGAT2GRM5ATMCYP2C9 | |
| SCHEMBL4741924 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KMT2AGRM5ATMSIRT2 | |
| SCHEMBL4741776 | 0.78 | CYP11B1 (0.41) | ALDH1A1GRM5ATMSIRT2SIRT1 | |
| SCHEMBL4741655 | 0.77 | LMNA (0.42) | ALDH1A1GRM5ATMSIRT2SIRT1 | |
| SCHEMBL4741489 | 0.77 | ALDH1A1 (0.48) | ALDH1A1DGAT2KMT2AGRM5ATM | |
| SCHEMBL4742091 | 0.73 | KMT2A (0.57) | ALDH1A1KMT2AGRM5ATMCYP2C9 | |
| SCHEMBL30581055 | 0.72 | ATM (0.50) | ALDH1A1KMT2AATMCYP2C9 | |
| SCHEMBL29073767 | 0.72 | ATM (0.50) | ALDH1A1KMT2AATMCYP2C9 | |
| SCHEMBL4745642 | 0.72 | ATM (0.42) | ALDH1A1GRM5ATMSIRT2SIRT1 | |
| SCHEMBL7257309 | 0.70 | KDM4E (0.42) | ALDH1A1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | ALDH1A1 2573/4885DGAT2 2721/4885KMT2A 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.